- Home
- RAPT vs ENTA Comparison
RAPT vs ENTA Comparison
Compare RAPT & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAPT
- ENTA
- Stock Information
- Founded
- RAPT 2015
- ENTA 1995
- Country
- RAPT United States
- ENTA United States
- Employees
- RAPT N/A
- ENTA N/A
- Industry
- RAPT Biotechnology: Pharmaceutical Preparations
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- RAPT Health Care
- ENTA Health Care
- Exchange
- RAPT Nasdaq
- ENTA Nasdaq
- Market Cap
- RAPT 117.5M
- ENTA 112.4M
- IPO Year
- RAPT 2019
- ENTA 2013
- Fundamental
- Price
- RAPT $0.89
- ENTA $5.93
- Analyst Decision
- RAPT Buy
- ENTA Buy
- Analyst Count
- RAPT 5
- ENTA 4
- Target Price
- RAPT $5.25
- ENTA $17.25
- AVG Volume (30 Days)
- RAPT 1.1M
- ENTA 119.2K
- Earning Date
- RAPT 05-08-2025
- ENTA 05-12-2025
- Dividend Yield
- RAPT N/A
- ENTA N/A
- EPS Growth
- RAPT N/A
- ENTA N/A
- EPS
- RAPT N/A
- ENTA N/A
- Revenue
- RAPT N/A
- ENTA $64,462,999.00
- Revenue This Year
- RAPT N/A
- ENTA N/A
- Revenue Next Year
- RAPT N/A
- ENTA N/A
- P/E Ratio
- RAPT N/A
- ENTA N/A
- Revenue Growth
- RAPT N/A
- ENTA N/A
- 52 Week Low
- RAPT $0.71
- ENTA $4.09
- 52 Week High
- RAPT $4.60
- ENTA $17.24
- Technical
- Relative Strength Index (RSI)
- RAPT 48.13
- ENTA 55.39
- Support Level
- RAPT $0.81
- ENTA $5.55
- Resistance Level
- RAPT $1.27
- ENTA $6.23
- Average True Range (ATR)
- RAPT 0.14
- ENTA 0.33
- MACD
- RAPT 0.01
- ENTA 0.05
- Stochastic Oscillator
- RAPT 31.55
- ENTA 75.31
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.